Bursitis
Drug research and approvals for bursitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 49 studies of bursitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 49
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Effects of Clinic Versus mHealth Application-Based Shoulder Rehabilitation in Patients With Adhesive CapsulitisNCT07921134 · Not applicable · Riphah International University · starts Nov 10, 2026
- Comparative Effects of Niel Asher Technique and Bowen Technique on Pain, Range of Motion and Functional Disability in…NCT07856173 · Not applicable · Foundation University Islamabad · starts Feb 12, 2026
- Maitland Mobilization With and Without Stroking Release Technique of Rotator Cuff Muscle in Frozen ShoulderNCT07854288 · Not applicable · Riphah International University · starts May 1, 2026
- Additional Effects of Thoracic Mobilization Versus Manipulation Along With Standard Physical Therapy in Adhesive…NCT07838610 · Not applicable · Foundation University Islamabad · starts Feb 12, 2026
- Pain Neuroscience Education and Graded Motor Imagery Combined With Conventional Physiotherapy on Diabetic Adhesive…NCT07763366 · Not applicable · Riphah International University · starts Nov 10, 2026
- Spinal Mobilization With Arm Movement and Kaltenborn Mobilization in Adhesive CapsulitisNCT07724691 · Not applicable · Riphah International University · starts Jul 1, 2026
- Transcutaneous Auricular Vagus Nerve Stimulation Added to Physiotherapy for Adhesive CapsulitisNCT07711353 · Not applicable · Muhsin Doran · starts Jun 10, 2026
- Comparison of Transcatheter Arterial Microembolization and Corticosteroid Injection and for Treatment of Frozen ShoulderNCT07696923 · Not applicable · Shin Kong Wu Ho-Su Memorial Hospital · starts Aug 1, 2026
- The Combined Effect of Mulligan Mobilization, Pain Neuroscience-Based Training, and Core Stabilization Exercises in…NCT07667556 · Not applicable · Yeditepe University · starts Apr 21, 2026
Approved 10
- Triamcinolone acetonideGlucocorticoid receptor agonist
- LidocaineSodium channel alpha subunit blocker
- DexamethasoneGlucocorticoid receptor agonist
- NaproxenCyclooxygenase inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- Methylprednisolone acetateGlucocorticoid receptor agonist
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- CapsaicinVanilloid receptor opener
- Methyl salicylate
Phase 3 1
- KetoprofenCyclooxygenase inhibitor
Phase 2 3
- Collagenase clostridium histolyticumCollagen hydrolytic enzyme
- AmitriptylineSerotonin transporter inhibitor
- AdalimumabTNF-alpha inhibitor
Phase 1 or earlier 1
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
How its trials ended
323 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 39 whose ending is known, 28% met their primary endpoint, 8% missed it and 64% stopped early.
- Completed, result not reported15247%
- Ongoing7523%
- Status unknown5718%
- Stopped: other or unclear124%
- Met its primary endpoint113%
- Stopped: enrollment or feasibility72%
- Stopped: sponsor or business decision41%
- Missed its primary endpoint31%
- Stopped: lack of efficacy21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA